Status:
COMPLETED
A Comparison of Rocuronium 0.6 mg/kg and Remifentanil 2 µg/kg in Elderly Patients Over 80 Years
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Neuromuscular Blockade
Intubation Complication
Eligibility:
All Genders
80+ years
Phase:
PHASE4
Brief Summary
The number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia. During anesthesia neuromuscular blocking agents (NMBA) are ad...
Detailed Description
The number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia within the next decades. Elderly patients are at higher risk of m...
Eligibility Criteria
Inclusion
- Age ≥ 80
- Scheduled for elective operations (expected duration of anesthesia \> 1 hour) under general anesthesia with intubation
- American Society of Anesthesiologists physical status classification (ASA) I to III
- Informed consent (see appendix 1)
- Read and understand Danish
Exclusion
- Neuromuscular disease
- Known allergy to rocuronium, remifentanil or sugammadex
- Rapid sequence induction
Key Trial Info
Start Date :
March 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 13 2020
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04287426
Start Date
March 11 2020
End Date
December 13 2020
Last Update
December 22 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100
2
Rigshospitalet, Glostrup
Glostrup Municipality, Denmark, 2600